Healthcare services company Cardinal Health will acquire Integrated Oncology Network (ION) for about $1.12 billion. A physician-led operator of community cancer centers, ION includes more than 50 ...
Copyright held by the owner/author(s).
Search for other works by this author on: ...
University of Arkansas for Medical Sciences, Little Rock, AR, United States ...
Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...
The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...
The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...
The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...
The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...
CDK2 inhibitors have received some attention at the 2024 ESMO Congress, with one candidate, PF-07104091, showing combination potential with CDK4-selective blockade in HR–positive, HER2–negative breast ...
Search for other works by this author on: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback